Evaluation of PAM Signaling Pathway Genetic Alterations and Their Clinical-Prognostic Relevance in Cervical Cancer
Евразийский онкологический журнал · 10.06.2026 · 14 (2) · 161-168
DOI: 10.34883/pi.2026.14.2.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Евразийский онкологический журнал, erschienen am 10.06.2026. Verfasst von K. Mardanova. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Purpose
This study aimed to evaluate the association between genetic alterations in the PI3K/AKT/mTOR (PAM) signaling pathway and overall survival (OS) in patients with cervical cancer. Materials and methods. A total of 116 HPV-negative female patients diagnosed with cervical cancer at the National Oncology Center (2017–2020) were included in this retrospective cohort study. DNA was extracted from FFPE tumor samples using Qiagen kits. Mutational analyses of PIK3CA, AKT1, PTEN, and mTOR genes were performed using real-time PCR (EntroGen) and RT-qPCR. Survival analyses were conducted using the Kaplan–Meier method and log-rank test.
Results
Patients without genetic alterations (wild-type) showed a median OS of 49.6 months, while those harboring at least one mutation had a markedly reduced median OS of 8.8 months (p
Zitieren
APA
Mardanova, K. (2026). Evaluation of PAM Signaling Pathway Genetic Alterations and Their Clinical-Prognostic Relevance in Cervical Cancer. Евразийский онкологический журнал, 14(2), 161-168. https://doi.org/10.34883/pi.2026.14.2.002
Vancouver
Mardanova K. Evaluation of PAM Signaling Pathway Genetic Alterations and Their Clinical-Prognostic Relevance in Cervical Cancer. Евразийский онкологический журнал. 2026;14(2):161-168. doi:10.34883/pi.2026.14.2.002
BibTeX
@article{Mardanova2026,
author = {Mardanova, K.},
title = {Evaluation of PAM Signaling Pathway Genetic Alterations and Their Clinical-Prognostic Relevance in Cervical Cancer},
journal = {Евразийский онкологический журнал},
year = {2026},
volume = {14},
number = {2},
pages = {161--168},
doi = {10.34883/pi.2026.14.2.002}
}
EUVIMED